
· updated
503A vs 503B Compounding: What It Means for Peptides
503A and 503B are the two legal lanes for compounded drugs in the US, and every peptide headline this year runs through one of them. A 503A pharmacy is the traditional kind: it makes a drug for one named patient from a valid prescription. A 503B “outsourcing facility” works more like a small manufacturer: it follows factory-grade quality rules, gets inspected by the FDA, and can ship to clinics without a patient name attached. The good news for anyone following BPC-157 and friends is that the legit path is getting clearer, and as of October 2026 it runs through 503A.
Key facts
- The split dates to 2013: the Drug Quality and Security Act, enacted Nov 27, 2013, created 503B outsourcing facilities as a new, voluntary category.
- 503A = one patient, one prescription: drugs must be compounded from valid patient-specific prescriptions, and these pharmacies are exempt from CGMP (the FDA’s manufacturing quality rules).
- 503B = factory rules, office stock allowed: outsourcing facilities must follow CGMP, are inspected by the FDA on a risk-based schedule, report adverse events, and can fill orders “for office stock.”
- The July 2026 vote was a 503A vote: on July 23 to 24, 2026 the FDA’s compounding advisory committee recommended 6 of 7 peptides for the 503A Bulks List (BPC-157, KPV and TB-500 by 8-6, MOTS-c by 7-5).
- Not legal to compound yet: the vote is nonbinding. The FDA still needs a proposed rule, a public comment period and a final rule.
- New in October: on Oct 7, 2026 the Washington Post reported the administration is drafting a plan to allow temporary sale of 7 previously restricted peptides through compounding pharmacies while the rules are written. Not announced yet.
What is a 503A pharmacy?
Think of your local compounding pharmacy. Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacist or physician can prepare a custom drug, but the FDA says one of the conditions is that “the drugs must be compounded based on the receipt of valid patient-specific prescriptions.” No prescription with your name on it, no compounded drug.
The raw ingredient (the FDA calls it a “bulk drug substance”) also has to qualify. Under 503A it must meet one of three conditions:
- It complies with a USP or NF monograph (an official quality standard), if one exists.
- It is a component of an FDA-approved drug, if there is no monograph.
- It appears on the FDA’s 503A Bulks List.
Most of the peptides people talk about at the gym have no monograph and are not in any approved drug. So for them, option 3 is the whole ballgame. That is why the Bulks List keeps showing up in the news. One exception worth knowing: sermorelin qualifies through option 2 because of its old FDA approval, which we break down in our sermorelin 503A explainer.
What is a 503B outsourcing facility?
503B was added in 2013 as a voluntary category. Facilities that sign up take on more rules in exchange for more reach. Per the FDA, “unlike compounders operating under section 503A, outsourcing facilities are subject to CGMP requirements,” the same quality system drug makers follow. They are inspected by the FDA on a risk-based schedule and must report adverse events and tell the FDA what they make.
In return, a 503B facility can fill an order from a hospital or clinic that is “not for an identified individual patient (e.g., for office stock).” That is how a clinic can have a compounded product on the shelf before a patient walks in.
The ingredient rules are different too. A 503B facility can only use a bulk substance if it is on the 503B bulks list, which is reserved for substances with “a clinical need,” or if the finished drug is on the FDA’s drug shortage list at the time of compounding. Shortage is the reason compounded semaglutide and tirzepatide were widely available for a while, a story we cover in compounded vs brand-name semaglutide.
503A vs 503B at a glance
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Who it serves | One named patient | Patients or clinics (office stock) |
| Prescription | Required, patient-specific | Not always tied to one patient |
| Quality rules | Exempt from CGMP | Must follow CGMP |
| FDA inspection | Not described on FDA’s page | Risk-based FDA schedule |
| Ingredient path | Monograph, approved-drug component, or 503A Bulks List | 503B bulks list (clinical need) or drug shortage |
What are Category 1 and Category 2?
While the FDA works through nominated ingredients, it sorts them into three buckets. Category 1 substances “may be eligible for inclusion,” and under its interim policy the FDA “does not intend to take action against a compounder” using them if the conditions are met. Category 2 is for substances where the FDA “has identified significant safety risks,” and compounders using them risk enforcement. Category 3 means the nomination lacked enough information. There is a separate set of categories for 503B. One more detail: the FDA says it does not intend to place substances nominated on or after Jan 7, 2025 into these categories.
Why the peptide vote is about 503A
The July 2026 advisory committee voted on the 503A Bulks List specifically. FDA staff had recommended against all seven peptides, calling the available studies “short in duration, small in sample size, and insufficient to establish safety or effectiveness.” The panel went the other way on six of them; emideltide (DSIP) was rejected 7-6. Full breakdown in our PCAC vote results.
If the FDA adopts those recommendations, the path would be a 503A one: a provider writes a prescription for a specific patient, and a licensed compounding pharmacy prepares it. Law firm Holland & Knight notes the FDA “is not obligated to follow the PCAC recommendations but often does,” and that the change has to go through notice-and-comment rulemaking. Past 503A rulemaking has not been fast: a February 2019 final rule placed six substances on the list, and for a September 2019 proposal to add five more, the FDA’s page (updated May 14, 2026) still says a final regulation will come after it considers comments.
What the October report could change
Update, Oct 30, 2026: HHS has now filed the policy, covering six peptides and excluding 503B outsourcing facilities. See what the HHS policy says. The rest of this section is kept as written.
The Oct 7 report describes a stopgap: certain previously restricted peptides could be sold temporarily through compounding pharmacies while the FDA writes the rules. Officials are reportedly discussing guardrails such as patient disclosures, adverse-event reporting and data collection. Supporters frame it as moving demand from the gray market into regulated pharmacies.
The honest caveats: the plan had not been formally announced as of Oct 8, it could still change, and the coverage we read does not name the seven peptides. FDA career scientists said in late June that the evidence was too weak to support compounding them. Access and proof are different things, and none of these peptides is FDA-approved. Our BPC-157 evidence review shows how thin the human data still is.
What it means for you
If a compounded peptide reaches you legitimately, it will almost certainly come with a prescription from a licensed provider and a 503A pharmacy label with your name on it. A product with no prescription, no pharmacy and a “not for human use” label is outside both lanes, whatever the news says. Payers generally treat compounded drugs as outside standard pharmacy coverage, so expect cash prices even after a final rule. If a peptide is on your radar, talk to a licensed provider, follow the live legal status tracker for changes, and see how peptides get prescribed.
Sources
- FDA: Human drug compounding laws (503A, 503B and the Drug Quality and Security Act)
- FDA: Bulk drug substances used in compounding under section 503A (updated May 14, 2026)
- FDA: Bulk drug substances used in compounding under section 503B
- AJMC: FDA panel backs 6 peptides for compounding (July 31, 2026)
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides (Aug 4, 2026)
- Zetik, summarizing the Washington Post: plan for temporary sale of 7 restricted peptides (Oct 8, 2026)
Educational content only, not medical advice or legal advice. Talk to a licensed provider about whether any medicine is right for you.